BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chasov V, Zaripov M, Mirgayazova R, Khadiullina R, Zmievskaya E, Ganeeva I, Valiullina A, Rizvanov A, Bulatov E. Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies. Front Immunol 2021;12:707734. [PMID: 34484205 DOI: 10.3389/fimmu.2021.707734] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Fine RL, Mao Y, Dinnen R, Rosal RV, Raffo A, Hochfeld U, Senatus P, Bruce JN, Nichols G, Wang H, Li Y, Brandt-Rauf PW. C-Terminal p53 Palindromic Tetrapeptide Restores Full Apoptotic Function to Mutant p53 Cancer Cells In Vitro and In Vivo. Biomedicines 2023;11. [PMID: 36672645 DOI: 10.3390/biomedicines11010137] [Reference Citation Analysis]
2 Mireștean CC, Iancu RI, Iancu DPT. p53 Modulates Radiosensitivity in Head and Neck Cancers-From Classic to Future Horizons. Diagnostics (Basel) 2022;12. [PMID: 36553058 DOI: 10.3390/diagnostics12123052] [Reference Citation Analysis]
3 Duffy MJ, Tang M, Rajaram S, O'Grady S, Crown J. Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use? Cancers (Basel) 2022;14:4499. [PMID: 36139658 DOI: 10.3390/cancers14184499] [Reference Citation Analysis]
4 Cui K, Yao X, Wei Z, yang Y, Liu X, Huang Z, Huo H, Tang J, Xie Y. Poor prognosis, hypomethylation, and immune infiltrates are associated with downregulation of INMT in head and neck squamous cell carcinoma. Front Genet 2022;13:917344. [DOI: 10.3389/fgene.2022.917344] [Reference Citation Analysis]
5 Mo X, Hu D, Li Y, Nai A, Ma F, Bashir S, Jia G, Xu M. A novel pyroptosis-related prognostic lncRNAs signature, tumor immune microenvironment and the associated regulation axes in bladder cancer. Front Genet 2022;13:936305. [DOI: 10.3389/fgene.2022.936305] [Reference Citation Analysis]
6 Peng M. Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile. Front Immunol 2022;13:970885. [DOI: 10.3389/fimmu.2022.970885] [Reference Citation Analysis]
7 Mazzotti L, Gaimari A, Bravaccini S, Maltoni R, Cerchione C, Juan M, Navarro EA, Pasetto A, Nascimento Silva D, Ancarani V, Sambri V, Calabrò L, Martinelli G, Mazza M. T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer. IJMS 2022;23:8590. [DOI: 10.3390/ijms23158590] [Reference Citation Analysis]
8 Song B, Wu P, Liang Z, Wang J, Zheng Y, Wang Y, Chi H, Li Z, Song Y, Yin X, Yu Z, Song B. A Novel Necroptosis-Related Gene Signature in Skin Cutaneous Melanoma Prognosis and Tumor Microenvironment. Front Genet 2022;13:917007. [DOI: 10.3389/fgene.2022.917007] [Reference Citation Analysis]
9 Kong Y, Xue Z, Wang H, Cui G, Chen A, Liu J, Wang J, Li X, Huang B. Identification of BST2 Contributing to the Development of Glioblastoma Based on Bioinformatics Analysis. Front Genet 2022;13:890174. [DOI: 10.3389/fgene.2022.890174] [Reference Citation Analysis]
10 Zhang Y, He R, Lei X, Mao L, Yin Z, Zhong X, Cao W, Zheng Q, Li D. Comprehensive Analysis of a Ferroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Landscape in Osteosarcoma. Front Oncol 2022;12:880459. [DOI: 10.3389/fonc.2022.880459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Liu S, Tang W, Cao J, Shang M, Sun H, Gong J, Hu B. A Comprehensive Analysis of HAVCR1 as a Prognostic and Diagnostic Marker for Pan-Cancer. Front Genet 2022;13:904114. [PMID: 35754803 DOI: 10.3389/fgene.2022.904114] [Reference Citation Analysis]
12 Wang CY, Chao CH. p53-Mediated Indirect Regulation on Cellular Metabolism: From the Mechanism of Pathogenesis to the Development of Cancer Therapeutics. Front Oncol 2022;12:895112. [PMID: 35707366 DOI: 10.3389/fonc.2022.895112] [Reference Citation Analysis]
13 Peng X, Xu Z, Guo Y, Zhu Y. Necroptosis-Related Genes Associated With Immune Activity and Prognosis of Colorectal Cancer. Front Genet 2022;13:909245. [DOI: 10.3389/fgene.2022.909245] [Reference Citation Analysis]
14 Huang L, Ge X, Liu Y, Li H, Zhang Z. The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy. Pharmaceutics 2022;14:1228. [PMID: 35745800 DOI: 10.3390/pharmaceutics14061228] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Swiatkowska A. p53 and Its Isoforms in Renal Cell Carcinoma—Do They Matter? Biomedicines 2022;10:1330. [DOI: 10.3390/biomedicines10061330] [Reference Citation Analysis]
16 Ustjanzew A, Sencio V, Trottein F, Faber J, Sandhoff R, Paret C. Interaction between Bacteria and the Immune System for Cancer Immunotherapy: The α-GalCer Alliance. Int J Mol Sci 2022;23:5896. [PMID: 35682578 DOI: 10.3390/ijms23115896] [Reference Citation Analysis]
17 Dou X, Sun X, Huang H, Jiang L, Jin Z, Liu Y, Zou Y, Li Z, Zhu G, Jin H, Jiao N, Zhang L, Liu Z, Zhang L. Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: Computational simulation, biological evaluation and cancer combinational chemotherapy study. European Journal of Medicinal Chemistry 2022;233:114196. [DOI: 10.1016/j.ejmech.2022.114196] [Reference Citation Analysis]
18 Yu C, Qi H, Zhang Y, Zhao W, Wu G. Elevated Expression of Gamma-Glutamyl Hydrolase Is Associated With Poor Prognosis and Altered Immune Signature in Uterine Corpus Endometrial Carcinoma. Front Genet 2021;12:764194. [PMID: 35082830 DOI: 10.3389/fgene.2021.764194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Kapoor S, Champion G, Basu A, Mariampillai A, Olnes MJ. Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cancers (Basel) 2021;13:5026. [PMID: 34638510 DOI: 10.3390/cancers13195026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Liang J, Zhang H, Huang Y, Fan L, Li F, Li M, Yan Y, Zhang J, Li Z, Yang X. A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy. Cancer Manag Res 2021;13:6977-87. [PMID: 34522140 DOI: 10.2147/CMAR.S330637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]